2003
DOI: 10.1046/j.0269-4727.2003.00512.x
|View full text |Cite
|
Sign up to set email alerts
|

Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia

Abstract: The transient endothelial dysfunction observed in hypertriglyceridemic subjects during post-prandial lipemia is mediated by post-prandial triglyceride increase and by the activation of inflammatory response. The anti-inflammatory activity of fenofibrate may represent an additional mechanism of its favorable action on the endothelial function during fasting and the post-prandial phase.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
29
0

Year Published

2005
2005
2019
2019

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(32 citation statements)
references
References 26 publications
3
29
0
Order By: Relevance
“…Our laboratory and others have found higher circulating sICAM-1 and sVCAM-1 in obese compared with normal weight adolescents (Desideri et al 2005;O'Brien et al 2006). Previous investigations have consistently shown increases in sICAM-1 and sVCAM-1 in diabetic and hypertriglyceridemic populations following an OFTT (Ceriello et al 2004;Marchesi et al 2003;Nappo et al 2002), suggesting increased endothelial cell activation in an already pro-atherosclerotic environment. In contrast, only small increases (Ceriello et al 2004;Nappo et al 2002), or no changes (Gill et al 2003a;Tsai et al 2004), have been observed in postprandial sICAM-1 and sVCAM-1 in healthy subjects.…”
Section: Discussionmentioning
confidence: 94%
“…Our laboratory and others have found higher circulating sICAM-1 and sVCAM-1 in obese compared with normal weight adolescents (Desideri et al 2005;O'Brien et al 2006). Previous investigations have consistently shown increases in sICAM-1 and sVCAM-1 in diabetic and hypertriglyceridemic populations following an OFTT (Ceriello et al 2004;Marchesi et al 2003;Nappo et al 2002), suggesting increased endothelial cell activation in an already pro-atherosclerotic environment. In contrast, only small increases (Ceriello et al 2004;Nappo et al 2002), or no changes (Gill et al 2003a;Tsai et al 2004), have been observed in postprandial sICAM-1 and sVCAM-1 in healthy subjects.…”
Section: Discussionmentioning
confidence: 94%
“…It has been shown both in vitro [46] and in vivo [47] that fibrates modulate monocyte recruitment by limiting the expression of leucocyte adhesion molecules on the surface of both endothelial cells and infiltrating mononuclear cells. Moreover, PPARα agonists reduce the release of matrix metalloproteinases by monocyte/macrophages [48]. Direct anti-atherogenic actions of PPARα agonists at the vascular wall [49] seem to be mediated by a reduction in the expression of inflammatory genes regulated by NF-κB [50][51][52].Finally, treatment with fibrates can improve FMD via regulating the balance between vasodilation and vasoconstriction.…”
Section: Discussionmentioning
confidence: 99%
“…29 We and others found that fenofibrate therapy significantly improved flow-mediated dilation ( Figure 1). 13,14,30 Plausible mechanisms for this include beneficial changes in lipoprotein levels. In support of this hypothesis, significant correlations between improvement in flow-mediated dilation and changes in total cholesterol, LDL cholesterol, and non-HDL cholesterol levels were observed.…”
Section: Effects On Vasomotor Functionmentioning
confidence: 99%